Sphere Fluidics, a Cambridge company commercialising single cell analysis systems, has closed a $40million investment round. It was co-led by Paris-based Sofinnova Partners and San Francisco investor Redmile Group.
Sphere Fluidics will use the money to expand its international sales activities in key markets and improve support for customers. It will also expand its product research and development programs, including novel applications for its proprietary Cyto-Mine® Single Cell Analysis System.
The Cyto-Mine is an automated, cost-effective platform that integrates single-cell screening, sorting, dispensing, imaging, and clone verification and has been purchased by an international customer base including global pharmaceutical companies, biotech, CDMOs, and leading research institutions.
The platform can process millions of samples per day, assessing and isolating rare or valuable cell variants or biological products to simplify and improve throughput across antibody discovery, cell line development and single-cell diagnostics.
The new funds raised will support ongoing commercialisation, broadening the technology’s adoption into new, innovative research areas such as cell therapy, synthetic biology and genome editing, in addition to ongoing enhancements of the platform’s capabilities and performance.
In conjunction with the financing, Sofinnova’s Tom Burt and Redmile Group’s Rob Faulkner will join the Board.
Frank Craig, CEO of Sphere Fluidics, said: “This funding round is not only testament to the potential of Sphere Fluidics’ single-cell analysis technology, but also to the expertise of our team.
“The investment will underpin our growth strategy, enabling us to expand both our product range and our support to new and existing customers, globally.”
